|
| Coronary artery disease (CAD) | | | |
|
| Iran | Age-adjusted prevalence (%) | 12.7 | Nabipour et al. [73] |
| Jordan | Prevalence (%) | 5.9 | Nsour et al. [74] |
|
| Saudi Arabia, | | | |
| (rural) | Prevalence (%) | 4.0 | Al-Nozha et al. [75] |
| (urban) | Prevalence (%) | 6.2 | |
| (overall) | Prevalence (%) | 5.5 | |
|
| Tunisia | Prevalence (%), [men] | 12.5 | Ben Romdhane et al. [76] |
| Prevalence (%), [women] | 20.6 | |
|
| Cerebrovascular Accidents | | | |
|
| Bahrain | Age-adjusted incidence (per 100,000) | 96.2 | Al-Jishi and Mohan [77] |
| Iran | Age-adjusted incidence (per 100,000) | 61.5 | Ahangar et al. [78] |
| Kuwait | Age-adjusted incidence (per 100,000) | 92.2 | Abdul-Ghaffar et al. [79] |
| Libya | Age-adjusted incidence (per 100,000) | 114.2 | Radhakrishnan et al. [80] |
| Palestine | Age-adjusted incidence (per 100,000) | 62.7 | Sweileh et al. [81] |
| Qatar | Age-adjusted incidence (per 100,000) | 123.7 | Hamad et al. [82] |
| Saudi Arabia | Age-adjusted incidence (per 100,000) | 38.5 | Al-Rajeh et al. [83] |
|
| Hypertension (HTN) | | | |
|
| Algeria | Prevalence (%), [Age > 25] | 36.2 | Yahia-Berrouiguet et al. [84] |
| Bahrain | Prevalence (%), [Age > 20] | 42.1 | Al-Zurba [85] |
|
| Egypt | Age-adjusted prevalence (%) | 27.4 | Ibrahim et al. [86] |
| Prevalence (%), [Age > 25] | 26.3 | Galal [87] |
|
| Iran | Prevalence (%), [Age > 19] | 25.6 | Sarraf-Zadegan et al. [88] |
| Prevalence (%), [Age: 30–55] | 23.0 | Haghdoost et al. [89] |
| Prevalence (%), [Age > 55] | 49.5 | |
|
| Iraq | Prevalence (%), [Age > 20] | 19.3 | WHO: STEPwise, [90] |
| Jordan | Prevalence (%), [Age > 18] | 30.2 | Zindah et al. [91] |
| Lebanon | Prevalence (%), [Age: 18–65] | 31.2 | Sibai et al. [92] |
| Morocco | Prevalence (%), [Age > 20] | 33.6 | Tazi et al. [93] |
| Oman | Prevalence (%), [Age > 20] | 21.5 | Hasab et al. [94] |
|
| Palestine (WB), | | | |
| (rural) | Prevalence (%), [Age: 30–65] | 25.4 | Abdul-Rahim et al. [95] |
| (urban) | Prevalence (%), [Age: 30–65] | 21.5 | |
|
| Qatar | Prevalence (%), [Age: 25–65] | 32.1 | Bener et al. [96] |
| Saudi Arabia | Prevalence (%), [Age: 30–70] | 26.1 | Al-Nozha et al. [97] |
| Sudan | Prevalence (%), [Age: 25–64] | 23.6 | WHO: STEPwise, [90] |
| Syria | Prevalence (%), [Age: 18–65] | 40.6 | Maziak et al. [98] |
| Turkey | Age-adjusted prevalence (%) | 25.7 | Sonmez et al. [99] |
| UAE | Prevalence (%), [Age > 20] | 20.8 | Baynouna et al. [100] |
| Yemen | Prevalence (%), [Age > 35] | 26.0 | Gunaid and Assabri [101] |
| Middle East | Prevalence (%), (overall) | 21.7 | Motlagh et al. [102] |
|
| Metabolic Syndrome | | | |
|
| Algeria | Prevalence (%), [Age > 20] | 17.4 | Mehio Sibai et al. [103] |
| Iran | Prevalence (%), [Age > 19] | 23.3 | Mehio Sibai et al. [103] |
| Jordan | Prevalence (%), [Age > 18] | 36.3 | Khader et al. [104] |
| Kuwait | Prevalence (%), [Age > 20] | 24.8 | Al Rashdan and Al Nesef [105] |
| Lebanon | Prevalence (%), [Age: 18–65] | 25.4 | Mehio Sibai et al. [103] |
| Morocco, (rural) | Prevalence (%), [women] | 16.3 | Rguibi and Belahsen [106] |
|
| Oman, | | | |
| (overall) | Prevalence (%), [Age > 20] | 21.0 | Al-Lawati et al. [107] |
| (Nizwa) | Age adjusted prevalence (%) | 8.0 | Al-Lawati et al. [107] |
|
| Palestine (WB) | Prevalence (%), [Age: 30–65] | 17.0 | Abdul-Rahim et al. [95] |
|
| Qatar | Prevalence (%), [Age > 20] | 27.7 | Musallam et al. [108] |
| Age adjusted prevalence (%) | 26.5 | Bener et al. [109] |
|
| Saudi Arabia | Age adjusted prevalence (%) | 39.3 | Al-Nozha et al. [110] |
| Tunisia | Prevalence (%), [Age > 20] | 16.3 | Bouguerra et al. [111] |
| UAE | Prevalence (%) | 39.6 | Malik and Razig [112] |
|
